Matthew L. Trerotola
Also at Enovis Corp
About
Matthew L. Trerotola has been at the helm of Enovis Corporation since July 2015, where he serves as both Chief Executive Officer and Chair of the Board. His leadership at ENOV marks a significant phase in the company’s development, with his appointment driving strategic changes and growth initiatives.
Before joining ENOV, he built a robust career through senior roles at several prestigious companies. At DuPont, he served as an Executive Vice President responsible for the Electronics & Communications and Safety & Protection segments, along with oversight of the Asia-Pacific business. Earlier roles at Danaher Corporation, including Vice President and Group Executive for Life Sciences, as well as positions leading product identification and business operations, further showcase his extensive experience in the industry.
In addition to his executive roles, he is an active board member of AptarGroup, Inc., highlighting his broader influence in the corporate world. With a strong educational foundation from Harvard Business School and the University of Virginia, his career reflects a blend of advanced business acumen and technical expertise, positioning him as a seasoned leader in both operational and strategic capacities.
$ENOV Performance Under Matthew L. Trerotola
Past Roles
| Organization | Role | Date Range | Details |
|---|---|---|---|
| DuPont | Executive Vice President and Member of the Office of the Chief Executive | 2013 – 2015 | Oversaw the Electronics & Communications and Safety & Protection segments and managed the Asia-Pacific business |
| Danaher Corporation | Vice President and Group Executive for Life Sciences | 2012 – 2013 | Held a leadership role focusing on strategic development in life sciences |
| Danaher Corporation | Group Executive, Product Identification | 2009 – 2012 | Focused on product identification and strategic guidance |
| Danaher Corporation | President of the Videojet Business | 2007 – 2009 | Led the Videojet business with emphasis on innovation and market growth |
| McKinsey & Company | Consultant | 1995 – 1999 | Advised industrial companies to accelerate growth |
External Roles
| Organization | Role | Date Range | Details |
|---|---|---|---|
| AptarGroup, Inc. | Director | 2022 – Present | Active role outside of ENOV |
Fixed Compensation
| Component Name | Amount | Payment Schedule | Additional Details |
|---|---|---|---|
| Base Salary | $1,077,000 | Annual | Fixed annual base salary |
| Company 401(k)/Deferred Compensation Plan Match and Contribution | $129,442 | Annual | Includes both match and contribution components |
| Auto Allowance | $20,000 | Annual | Annual cash allowance for car-related expenses pursuant to his employment contract |
| Financial Services | $15,250 | Annual | Reimbursement for financial planning services |
| Aircraft Usage | $282,344 | Annual | Company expenses incurred for private plane usage for personal travel; billed directly |
| Supplemental Long-Term Disability Premiums | $6,472 | Annual | Premium payments for supplemental long-term disability insurance |
| Group Term Life Insurance | $8,748 | Annual | Premiums for a life insurance benefit equal to 1.5 times salary, capped at $1,125,000 |
Performance Compensation
Performance-Based Restricted Stock Units (PRSUs)
| Parameter | Value | Details |
|---|---|---|
| Metric | Relative Total Shareholder Return (TSR) vs. S&P 500 Health Care Equipment & Supplies Industry Index | Determines the payout scale based on percentile performance |
| Payout Scale | Below Threshold: 0%; Threshold (30th percentile): 50%; Target (55th percentile): 100%; Maximum (>80th percentile): 200% (capped at 100% if absolute TSR is negative) | Detailed performance brackets |
| Grant Date | February 28, 2023 | The date the award was granted |
| Grant Date Fair Value | $4,052,607 | The fair value assigned on the grant date |
| Grant Date Stock Price | $57.62 per share | Reflects the exercise price for related stock options |
| Number of PRSUs | Threshold: 28,222; Target: 56,443; Maximum: 112,886 | Varies by performance outcome |
| Vesting | Cliff vest at end of a three-year performance period | Contingent upon certification by the CHCM Committee |
Annual Incentive Plan (AIP)
| Parameter | Value | Details |
|---|---|---|
| Performance Metric 1 | Net Sales (as adjusted) | Weight: 40%; Threshold: $1.588 billion; Target: $1.654 billion; Maximum: $1.786 billion; Achieved: $1.693 billion; CPF: 123% |
| Performance Metric 2 | Adjusted EBITDA | Weight: 60%; Threshold: $228 million; Target: $260 million; Maximum: $325 million; Achieved: $269 million; CPF: 121% |
| Weighted Aggregate CPF | 122% | Combined corporate performance factor |
| Bonus Calculation | Base Salary: $1,077,000; Target Bonus Percentage: 125%; Target Bonus: $1,346,250; Bonus Before IPF: $1,642,425; Individual Performance Factor: 110%; Executive Bonus Payment: $1,806,668 | Bonus metrics derived from performance results |
| Equity Grant Details | PRSUs: $4,052,607; RSUs: $1,626,094; Stock Options: $1,750,010 | Grant Date: February 28, 2023; Stock Options vest ratably over three years starting on February 28, 2024 |
*Note: All performance compensation metrics reflect the 2023 awards with performance evaluations based on both operational and financial targets, and vest over varying periods as noted above. *